Yoakum County Hospital

CLIA Laboratory Citation Details

3
Total Citations
15
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 45D0674582
Address 412 Mustang Ave, Denver City, TX, 79323
City Denver City
State TX
Zip Code79323
Phone(806) 592-2121

Citation History (3 surveys)

Survey - February 11, 2025

Survey Type: Standard

Survey Event ID: 1ZC511

Deficiency Tags: D0000 D5801

Summary:

Summary Statement of Deficiencies D0000 An onsite recertification survey conducted February 11, 2025 found the laboratory in compliance with 42 CFR Part 493, Requirements for Laboratories. D5801 TEST REPORT CFR(s): 493.1291(a) (a) The laboratory must have an adequate manual or electronic system(s) in place to ensure test results and other patient-specific data are accurately and reliably sent from the point of data entry (whether interfaced or entered manually) to final report destination, in a timely manner. This includes the following: (a)(1) Results reported from calculated data. (a)(2) Results and patient-specific data electronically reported to network or interfaced systems. (a)(3) Manually transcribed or electronically transmitted results and patient-specific information reported directly or upon receipt from outside referral laboratories, satellite or point-of-care testing locations. This STANDARD is not met as evidenced by: Based on a review of analytic patient testing records, patient chart reviews, and interview with laboratory staff, the laboratory failed to ensure two of five patient test results reivewed between May 2024 and July 2024 were entered into the patient's record. The findings included: 1. Based on review of the laboratory's analtyic records and patient chart reviews, the following patient blood gas reports had not been entered into the patient chart: Visit ID: 00258305 MR: 00009539 Time and Date: 11:18 hours on 5/8/2024 Visit ID: 00262288 MR 00034362 Time and Date: 11:23 hours on 7/25 /2024 2. In an interview at 14:00 hours on 2/11/2025, the Respiratory Therapy Manager explained that all blood gas results had to be scanned into the patient chart by medical records deptarment as the blood gas analzyer did not have the software to transmit results directly. She confirmed the patients listed above had been tested, but the results had not been entered into the patient's respective charts. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - August 3, 2022

Survey Type: Special

Survey Event ID: 9QC311

Deficiency Tags: D2016 D2096 D6000 D6016 D6016 D0000 D2016 D2096 D6000

Summary:

Summary Statement of Deficiencies D0000 Based on a proficiency testing desk review survey performed on August 4, 2022, the laboratory was found to be out of compliance based on the following CONDITION LEVEL DEFICIENCIES: D2016 - 42 C.F.R. 493.803 Condition: Successful participation D6000 - 42 C.F.R. 493.1403 Condition: Laboratory Director, moderate complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Association of Bioanalysts evaluation reports, the laboratory failed to achieve successful Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- performance in two of two consecutive testing events for the specialty Routine Chemistry for the analyte Bilirubin, Total, resulting in unsuccessful performance. Refer to D2096. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Association of Bioanalysts evaluation reports, the laboratory failed to achieve successful performance in two of two consecutive testing events for the specialty Routine Chemistry for the analyte Bilirubin, Total, resulting in unsuccessful performance. The finding included: 1. Based on review of the American Association of Bioanalysts evaluation reports for the first and second events of 2022, the laboratory received the following unsatisfactory scores for the analyte Bilirubin, Total: 1) First event of 2022, Bilirbuin, Total - score of 0 percent 3) Second event of 2022, Bilirubin, Total - score of 20 percent D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Association of Bioanalysts evaluation reports, the laboratory director failed to ensure successful participation in an HHS approved proficiency testing program for analyte Bilirubin, Total in the specialty of Routine Chemistry for two of two events in 2022. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on desk review of the Certification and Survey Provider Enhanced Reporting -- 2 of 3 -- (CASPER) Report 155 Individual Laboratory Profile and American Association of Bioanalysts proficiency testing records, the laboratory director failed to ensure successful participation in a HHS approved proficiency testing program for analyte Bilirubin, Total in the specialty of Routine Chemistry for two of two events in 2022. Refer to D2096. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - October 21, 2021

Survey Type: Standard

Survey Event ID: I1T611

Deficiency Tags: D5441 D6046 D5441 D6046

Summary:

Summary Statement of Deficiencies D5441 CONTROL PROCEDURES CFR(s): 493.1256(a)(b)(c)(g) (a) For each test system, the laboratory is responsible for having control procedures that monitor the accuracy and precision of the complete analytic process. (b) The laboratory must establish the number, type, and frequency of testing control materials using, if applicable, the performance specifications verified or established by the laboratory as specified in 493.1253(b)(3). (c) The control procedures must-- (c)(1) Detect immediate errors that occur due to test system failure, adverse environmental conditions, and operator performance. (c)(2) Monitor over time the accuracy and precision of test performance that may be influenced by changes in test system performance and environmental conditions, and variance in operator performance. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on review of quality control results and interview, the laboratory failed to monitor over time the accuracy and precision of the test system for D-Dimer performed on the Triage Meter using the Triage Control Total 5 for 2 of 2 years reviewed. Findings follow. A. Review of monthly quality control showed mean and standard deviation (SD) were not calculated for the D-Dimer quality control results. B. Interview with the Technical Consultant on Oct 19, 2021 at 1645 in the laboratory confirmed statistical analysis was not performed on the D-Dimer quality control results. D6046 TECHNICAL CONSULTANT RESPONSIBILITIES CFR(s): 493.1413(b)(8) (b) The technical consultant is responsible for-- (b)(8) Evaluating the competency of all testing personnel and assuring that the staff maintain their competency to perform test procedures and report test results promptly, accurately and proficiently. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- This STANDARD is not met as evidenced by: Based on review of competency evaluations and interview, the technical consultant failed to perform the competency evaluations for four out of five randomly selected competency evaluations from 2021. Findings follow. A. Review of competency evaluations from 2021 showed the following competency evaluations were performed by the following testing personnel in the laboratory as listed on the CMS form 209: 2021 Competency Evaluations: 1. Testing personnel #3 performed PT/APTT, CBC with retic, D-Dimer, sed rate competencies by testing personnel #2, 2. Testing personnel #4 performed PT/APTT, CBC with retic, RPR, and C diff competencies by testing personnel #7, 3. Testing personnel #5 performed Dimension EXL, PT/APTT, and RPR competencies by testing personnel #4, 4. Testing personnel #6 performed PT /APTT, Dimension EXL, and RPR competencies by testing personnel #4. B. Interview with the Technical Consultant on Oct 19, 2021 at 1145 in the office confirmed the competency evaluations were not always performed by her, and acknowledged when a tech was available, they would perform competencies. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access